

**6. LITERATURVERZEICHNIS**

- Alexanian R und Dimopoulos M. The treatment of Multiple Myeloma. *NEJH*. 1994;330:484-489.
- Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. *Oncogene*. 2005;24:7455-7464.
- Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. *Blood*. 2004;103:20-32.
- Barnett SF, Defeo-Jones D, Fu S, et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. *Biochem J*. 2005;385:399-408.
- Bellacosa A, Kumar CC, Di Christofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. *Adv Cancer Res*. 2005;94:29-86.
- Bergsagel LP and Kuehl MW. Molecular pathogenesis and a consequent classification of Multiple Myeloma. *J Clin Oncol*. 2005;23:6333-6338.
- Brazil DP, Yang Z-Z, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. *Trends Biochem Sci*. 2004;29:233-242.
- Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. *Science*. 2002;296:550-553.
- Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell*. 1999;96:857-868.
- Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. *Nature*. 2007;448:439-444.
- Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, Stewart AK. Analysis of *PTEN* deletions and mutations in multiple myeloma. *Leuk Res*. 2006;30:262-265.
- Chatterjee M, Hönemann D, Lentzsch S, et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. *Blood*. 2002;100:3311-3318.
- Chatterjee M, Stühmer T, Herrmann P, Bommert K, Dörken B, Bargou RC. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. *Blood*. 2004;104:3712-3721.
- Chen ML, Xu PZ, Peng XD, et al. The deficiency of *Akt1* is sufficient to suppress tumor development in *Pten*<sup>+/-</sup> mice. *Genes & Dev*. 2006;20:1569-1574.

- Chen WS, Xu PZ, Gottlob K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene. *Genes & Dev.* 2001;15:2203-2208.
- Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of *AKT2* in human pancreatic cancer cells and inhibition of *AKT2* expression and tumorigenicity by antisense RNA. *Proc Natl Acad Sci USA.* 1996;93:3636-3641.
- Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. *Blood.* 2001;3:729-736.
- Cho H, Thorvaldsen JL, Chu Q, et al. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. *J Biol Chem.* 2001;276:38349-38352.
- Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). *Science.* 2001;292:1728-1731.
- Czauderna F, Fechtner M, Aygün H, et al. Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. *Nucleic Acids Res.* 2003;31:670-682.
- DeFeo-Jones D, Barnett SF, Fu S, et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. *Mol Cancer Ther.* 2005 Feb;4(2):271-279.
- Di Cristofano A und Pandolfi PP. The multiple roles of PTEN in tumor suppression. *Cell.* 2000.18;100:387-390.
- Dong LQ und Liu F. PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. *Am J Physiol Endocrinol Metab.* 2005;289:187-196.
- Easton RM, Cho H, Roovers K, et al. Role for Akt3/protein kinase B in attainment of normal brain size. *Mol Cell Biol.* 2005;25:1869-1878
- Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of Multiple Myeloma: a workshop report. *Cancer Res.* 2004;64:1546-1558.
- Franke TF, Yang SI, Chan TO, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. *Cell* 1995;81:727-736.
- Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. *Mol Cell.* 2005;18:13-24.

- Gattenloehner S, Chuvpilo S, Langebrake C, et al. Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression. *Blood*. 2007;110:2027-2033.
- Gunn WG, Conley A, Deininger L, et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. *Stem Cells*. 2006;24:986-991.
- Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. *Blood*. 1998;91:3-21.
- Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. *Oncogene*. 2001;20:5991-6000.
- Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. *Blood*. 2004;104:607-618.
- Hidesima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. *Blood*. 2006;107:4053-4062.
- Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. *Nat Rev Cancer*. 2007;7:585-598.
- Hsu J-H, Shi Y, Krajewski S, et al. The AKT kinase is activated in multiple myeloma tumor cells. *Blood*. 2001;98:2853-2855.
- Hsu J-H, Shi Y, Hu L, Fisher M, Franke TF, Lichtenstein A. Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses. *Oncogene*. 2002;21:1391-1400.
- Hyun T, Yam A, Pece S, et al. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. *Blood*. 2000;96:3560-3568.
- Knop S, Gerecke C, Topp MS, et al. Lenalidomode (Revlemid™), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma-first results of a German multicenter phase I/II trial [abstract]. *Blood*. 2006;108:408.
- Krutzik PO, Irish JM, Nolan GP, Perez OD. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. *Clin Immunol*. 2004;3:206-221.

- Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. *Hematology Am Soc Hematol Educ Program*. 2005;346-352.
- Kumar CC, Madison V. AKT crystal structure and AKT-specific inhibitors. *Oncogene*. 2005;24:7493-7501.
- Kyle RA und Rajkumar SV. Multiple Myeloma. *N Engl J Med*. 2004;351:1860-1873.
- Lentzsch S, Chatterjee M, Gries M, et al. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. *Leukemia*. 2004;18:1883-1890.
- Li J, Simpson L, Takahashi M, et al. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/ protein kinase B oncogene. *Cancer Res*. 1998;58:5667-5672.
- Lindsley CW, Zhao Z, Leister WH, et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. *Bioorg Med Chem Lett*. 2005;15:761-764.
- Lindsley CW, Barnett SF, Yaroschak M, Bilodeau MT, Layton ME. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. *Curr Top Med Chem*. 2007;7:1349-1363.
- Lu Y, Lin YZ, La Pushin R, et al. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. *Oncogene*. 1999;18:7034-7045.
- Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. *Cancer Cell*. 2004;5:221-230.
- Momota H, Nerio E, Holland EC. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with Temozolomide to arrest cell proliferation in gliomas in vivo. *Cancer Res*. 2005;65:7429-7435.
- Nakatani K, Thompson DA, Barthel A, et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. *J Biol Chem*. 1999;274:21528-21532.
- Neri A, Murphy JP, Cro L, et al. Ras oncogene mutation in multiple myeloma. *J Exp Med*. 1998;170:1715-1725.
- Pene F, Claessens Y-E, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. *Oncogene*. 2002;21:6587-6597.

- Prokop DJ. Marrow stromal cells as stem cells for nonhemapoetic tissues. *Science*. 1997;276:71-74.
- Reece DE. Management of multiple myeloma: the changing landscape. *Blood*. 2007; 6:301-314
- Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *N Engl J Med*. 2005;352:2487-2489.
- Rommel C, Clarke BA, Zimmermann S, et al. Differentiation stage-specific inhibition of the Raf- MEK-ERK pathway by Akt. *Science*. 1999;286:1738–1741.
- Sanderson RD, Turnbull JE, Gallagher JT, Lander AD. Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. *J Biol Chem*. 1994;269:13100-13106.
- Smith A, Wisloff F, Samson D, et al. Guidelines on the diagnosis and management of multiple myeloma 2005. *Br J Haematol*. 2006;132:410-451.
- Sporeno E, Savino R, Ciapponi L, et al. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. *Blood*. 1996;87:5410-5419.
- Stühmer T, Chatterjee M, Hildebrandt M, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. *Blood*. 2005;106:3609-3617.
- Sun M, Wang G, Paciga JE, et al. AKT1/PKBa kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. *Am J Pathology*. 2001;159:431-437.
- The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. *Br J Haematol*. 2003;121:749-757.
- Toker A und Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. *Cancer Res*. 2006;8:3963-3966.
- Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. *Cancer Res*. 2000;60:6763-6770.
- Whang YE, Yuan XJ, Liu Y, et al. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor. *Vitam Horm*. 2004;67:409-426.
- Yuan Z, Sun M, Feldman RI, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. *Oncogene*. 2000;19:2324-2330.